Identification of Circulating Tumor Cells in Patients with Lung Cancer using DNA Aptamers

Abstract

BACKGROUND: Lung cancer (LC) is one of the most prevalent types of cancer, with mortality rates reaching 25% of all cancer-related deaths. The majority of patients are classified as stage IV at the time of diagnosis, a stage at which the probability of successful treatment is considerably low. Conventional diagnostic methods for lung cancer are expensive, labor-intensive, and highly invasive if a biopsy is performed. Consequently, liquid biopsy, which involves the extraction of circulating tumor cells from blood samples, has emerged as a pivotal area of research in oncology.

AIM: To develop a method for the isolation and identification of circulating tumor cells in the peripheral blood of patients with lung cancer using DNA aptamers.

MATERIALS AND METHODS: The study objects are lung cancer tissue, blood of patients with lung cancer and primary lung cancer cell culture. Gold-decorated magnetic nanoparticles and thiolated aptamers LC-17, LC-183 and LC-224 were used to isolate proteins. A hybrid of a thiol primer and a non-specific DNA sequence composed of two AG nucleotide repeats was used as a control. Mass spectrometry was performed using UltiMate 3000 nano-UHPLC system coupled with Orbitrap Fusion mass spectrometer (Thermo Scientific, USA). Circulating tumor cell counts were measured on CytoFLEX flow cytometer (Beckman Coulter, USA) after triple staining. Fluorescence microscopy was used for CSC visualization.

RESULTS: The potential protein targets of the aptamers LC-17, LC-183, and LC-224 were identified. These aptamers were then used to isolate circulating tumor cells from the blood of patients with lung cancer. The identification of circulating tumor cells was performed using flow cytometry and fluorescence microscopy.

CONCLUSIONS: The proposed method for the identification of circulating tumor cells through magnetic separation and flow cytometry provides a quantitative analysis of the target analyte, facilitated by the use of cell-specific lung cancer aptamers, including LC-17, LC-183, and LC-224, which exhibit high-affinity binding properties.

Keywords

lung cancer / circulating tumor cells / magnetic separation / DNA aptamers / flow cytometry

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. СA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660

[2] Zukov RA, Safontsev IP, Klimenok MP, et al. Analysis of lung cancer morbidity in Krasnoyarsk Krai. Justification for the implementation of innovative methods for early diagnosis. Russ Oncol J. 2023;27(4):171–181. EDN: HPOCPH doi: 10.17816/onco479913

[3] Kratzer TB, Bandi P, Freedman ND, et al. Lung cancer statistics. Cancer. 2024;130(8):1330–1348. doi: 10.1002/cncr.35128

[4] Fiorentino FP, Macaluso M, Miranda F, et al. CTCF and BORIS Regulate Rb2/p130 M.Gene Transcription: A Novel Mechanism and a New Paradigm for Understanding the Biology of Lung Cancer. Mol Cancer Res. 2011;9:225–233. doi: 10.1158/1541-7786.MCR-10-0493

[5] Zhao Q, Yuan Z, Wang H, et al. Role of circulating tumor cells in diagnosis of lung cancer: a systematic review and meta-analysis. J Int Med Res. 2021;49(3):300060521994926. doi: 10.1177/0300060521994926

[6] Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021;11(4):858–873. doi: 10.1158/2159-8290.CD-20-1311

[7] Revelo AE, Martin A, Velasquez R, et al. Liquid biopsy for lung cancers: an update on recent developments. Ann Transl Med. 2019;7:349. doi: 10.21037/atm.2019.03.28

[8] Chen F, Ni Y, Zhang J, et al. The value of folate receptor-positive circulating tumour cells as a diagnostic biomarker for lung cancer: a systematic review and meta-analysis. J Int Med Res. 2023;51(9):3000605231199763. doi: 10.1177/03000605231199763

[9] Tong B, Wang M. Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine. Future Oncol. 2019;15:2531–2542. doi: 10.2217/fon-2018-0548

[10] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–196. doi: 10.1038/nrm3758

[11] Xiao X, Li H, Zhao L, et al. Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications. Biomed Pharmacother. 2021;143:112232. doi: 10.1016/j.biopha.2021.112232

[12] Sabri MZ, Hamid AAA, Hitam SMS, Rahim MZA. The assessment of three dimensional modelling design for single strand DNA aptamers for computational chemistry application. Biophys Chem. 2020;267:106492. doi: 10.1016/j.bpc.2020.106492

[13] Berezovski MV, Lechmann M, Musheev MU, et al. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc. 2008;130(28):9137–9143. doi: 10.1021/ja801951p

[14] Li W, Liu JB, Hou LK, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1):25. doi: 10.1186/s12943-022-01505-z

[15] Ahn JC, Teng PC, Chen PJ, et al. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology. 2021;73:422–436. doi: 10.1002/hep.31165

[16] Dall’Olio FG, Marabelle A, Caramella C, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19:75–90. doi: 10.1038/s41571-021-00564-3

[17] Su Z, Wang Z, Ni X, et al. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. Clin Cancer Res. 2019;25:5049–5060. doi: 10.1158/1078-0432.CCR-18-3571

[18] Zamay GS, Kolovskaya OS, Zamay TN, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Mol Ther. 2015;23:1–11. doi: 10.1038/mt.2015.108

[19] Lokman NA, Ween MP, Oehler MK, et al. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011;4(2):199–208. doi: 10.1007/s12307-011-0064-9

[20] Fan C, Lin X, Wang E. Clinicopathological significance of cathepsin D expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study. Tumour Biol. 2012;33(4):1045–1052. doi: 10.1007/s13277-012-0338-y

[21] Berr AL, Wiese K, Dos Santos G, et al. Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer. Oncogene. 2023;42(25):2074–2087. doi: 10.1038/s41388-023-02703-9

[22] Lee HW, Park YM, Lee SJ, et al. Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma. Clin Cancer Res. 2013;19:5879–5889. doi: 10.1158/1078-0432.CCR-13-1181

[23] Lopes D, Maiato H. The Tubulin Code in Mitosis and Cancer. Cells. 2020,9(11):2356. doi: 10.3390/cells9112356

[24] Kim Y, Jang HH. The role of peroxiredoxin family in cancer signaling. J Cancer Prev. 2019;24(2):65. doi: 10.15430/JCP.2019.24.2.65

[25] Peng L, Xiong Y, Wang R, et al. The critical role of peroxiredoxin-2 in colon cancer stem cells. Aging (Albany NY). 2021;13(8):11170. doi: 10.18632/aging.202784

[26] Kunii T, Ogura M, Mie E., et al. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst. 2011;136:1310–1312. doi: 10.1039/c0an00962h

Funding

Министерство здравоохранения РФMinistry of Health of the Russian Federation(REYC-2023-0012)

RIGHTS & PERMISSIONS

Eco-Vector